VVOS Earnings

VVOS reported its FY2025Q3 earnings on 2025-11-19, showcasing a revenue of 6.78M against an estimate of 4.71M, resulting in a 43.95% surprise. The EPS was -0.49, surpassing the expected -0.53 by 7.55%. The stock experienced a -10.17% price change on the earnings day and a -6.78% change over the next five days, reflecting market reactions to the results.

Following VVOS's FY2025Q3 earnings announcement on 2025-11-19, the stock price moved by -10.17% on the day of the release. Over the subsequent five days, it saw a -6.78% change. Historically, VVOS's stock price tends to shift by an average of -1.07% in the 10 days leading up to earnings and 14.87% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate VVOS's annual revenue to reach 6.25M, while the EPS is projected at -0.41. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between VVOS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, VVOS's stock price typically moves by -1.07% in the 10 days before its earnings and 14.87% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.41 and revenue of 6.25M.

The earnings call reveals significant financial challenges: a 50.5% increase in operating expenses, a widened net loss, and substantial liabilities, which overshadow the 17% gross profit increase. The Q&A section highlights revenue drops due to provider absences and an unclear path to cash flow positivity. While there are growth prospects with new models and partnerships, the immediate financial health and guidance issues, coupled with increased debt, suggest a negative stock price reaction.